Partners4Access expands top leadership with new appointment
Partners4Access has announced the appointment of Alison Kneen as Vice President of International Operations to lead its rapidly expanding Market Access Orphan Drug Specialist team.
Alison brings extensive international market access experience built over the last 27 years from previous roles with IQVIA; Principal and Head of Market Access Strategic Consulting, as well as during her time within industry at GSK, Novartis, AstraZeneca, Grünenthal, SPMSD, and Baxalta where she held senior leadership positions working at Local, European & Global levels.
Speaking about the appointment, Sophie Schmitz, Managing Partner, P4A said, “I’m personally delighted that Alison has joined our growing team. True expertise in rare disease is hard to find, and Alison comes with a triad of clinical, industry and consulting excellence. This will help us continue to strengthen our client support and orphan drug knowledgebase.”
P4A has a strong reputation for appointing experienced individuals who are experts in orphan drug market access. Talent recruitment, growth and retention is an integral part of the company’s strategy to partner with clients and make a valuable difference in their rare disease strategies.
“I very much look forward to bringing the experience gained in market access over the last 27 years within industry and laterally consultancy to life. I feel my wealth of industry experience will assist me to strategically support our clients navigate the ever-increasing environmental health challenges to achieve commercial success”, Alison Kneen said.
P4A are specialists in orphan drug access, partnering with the biotechnology industry to support launches worldwide. Focus areas include: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at email@example.com or visit our website www.parntners4access.com